Altavant Sciences Acquires Onspira Therapeutics

Inspira Technologies to Acquire Advanced Liquid Biopsy Diagnostics Business and Invest $15 Million

January 5, 2026

Medical Devices

Inspira Technologies OXY B.H.N. Ltd. entered into a non-binding term sheet for a proposed two-part transaction: an all-share acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment at a $180 million pre-money valuation. The acquired platform uses AI-powered analysis of circulating tumor cells from standard blood samples, with an expected FDA clearance path via the 510(k) regulatory pathway and initial clinical focus on breast cancer.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Kindeva Drug Delivery Acquires Summit Biosciences

January 18, 2024

Healthcare Services

Kindeva Drug Delivery, an operating company of Altaris, LLC, acquired Summit Biosciences, a specialized intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. The deal expands Kindeva’s drug-delivery capabilities with a new intranasal drug-delivery platform and adds Summit’s FDA- and EMA-approved cGMP facility in Lexington, Kentucky.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Adalvo Acquires Branded Pain Product Onsolis

August 2, 2022

Pharmaceuticals

Adalvo has acquired full global rights to the branded opioid analgesic Onsolis from a U.S.-based specialty pharmaceutical owner, becoming the sole and exclusive owner of the product and assuming supply and market authorisation responsibilities worldwide. The product, indicated for management of breakthrough cancer pain in opioid-tolerant patients, is sold in several EU countries and Taiwan and Adalvo intends to integrate it into its expanding branded-product portfolio.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.